Neos Therapeutics

The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.  Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Worth area.

Emles Alpha Opportunities ETF

V-Shares US Leadership Diversity ETF

In recent months, ETF launches have accelerated, leaving advisors with the increasingly daunting task of sifting through the available offerings. Among the flood of new products are “hidden gems” that offer unique, differentiated approaches to risk management, income, ESG, and portfolio diversification.

Take Your Portfolio to the Next Level in 2022 With These Hidden Gems

Aytu BioScience

Bionano Genomics

Citius Pharmaceuticals

Denison Mines

Hall of Fame Resort & Entertainment

Ideanomics Inc

Marker Therapeutics Inc

Zomedica

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

10 Reddit Penny Stocks Seeing the Most Chatter Today

NEOS stock holders will get AYTU stock in this no-cash merger transaction. Today's vote has the support of two proxy advisory firms.

Merger News: Why NEOS Stock and AYTU Stock Are Climbing Today

Neos Therapeutics Inc (NASDAQ: NEOS) and Aytu BioScience Inc (NASDAQ: AYTU) shares are rising today in the premarket session, though there is no news on both companies. The investors are reacting to the companies' respective special meetings of stockholders related to the proposed merger between Aytu and Neos that will happen today.

Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today?

The stock price of Neos Therapeutics Inc (NASDAQ: NEOS) has increased by over 60% pre-market. This is why it happened.

NEOS Stock Price Increases Over 60% Pre-Market: Why It Happened

– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time –

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

– Record date for each Special Meeting of Stockholders is February 5, 2021 –

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

Canaan Inc.

New Gold

RF Industries

Westwater Resources

Penny stocks are wildly dangerous and not meant for risk-averse investors. Still, if you want to play, here are some ideas.

9 Penny Stocks to Buy If You Can Stomach Risk

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company by Aytu BioScience, Inc. (NASDAQ: AYTU). Stockholders will...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc.

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.

Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise. The post Neos Therapeutics News: Why NEOS Stock Is Soaring Today appeared first on InvestorPlace.

Neos Therapeutics News: Why NEOS Stock Is Soaring Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh

Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS

Neos Therapeutics' (NEOS) CEO Jerry McLaughlin on Q3 2020 Results - Earnings Call Transcript

DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its third quarter 2020 financial results at the opening of U.S. financial markets on Monday, November 9, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.

Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020

Cinedigm

Dynavax Technologies

Nokia

Rolls-Royce Holdings PLC

Titan Pharma

Waitr Holdings Inc

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

7 Penny Stocks to Watch in November

DALLAS and FORT WORTH, Texas, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m. ET.

Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2020 Results - Earnings Call Transcript

– Company to host conference call today at 8:30 a.m. EDT – – Company to host conference call today at 8:30 a.m. EDT –

Neos Therapeutics Reports Second Quarter 2020 Financial Results

DALLAS and FORT WORTH, Texas, Aug.  03, 2020  (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its second quarter 2020 financial results at the opening of U.S. financial markets on Monday, August 10, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.

Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020

DALLAS and FORT WORTH, Texas, June  16, 2020  (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020, at 4:30 p.m. ET.

Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference

Neos Therapeutics. Inc. (NEOS) CEO Jerry McLaughlin on Q1 2020 Results - Earnings Call Transcript

-- N-desethyloxybutynin is the active ingredient in NT0502, the company’s development candidate for the treatment of sialorrhea -- -- N-desethyloxybutynin is the active ingredient in NT0502, the company’s development candidate for the treatment of sialorrhea --

Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2019 Results - Earnings Call Transcript

News for Neos Therapeutics Stock (NEOS)